Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 30,600 shares, a decrease of 28.2% from the March 31st total of 42,600 shares. Based on an average daily volume of 27,700 shares, the short-interest ratio is presently 1.1 days. Approximately 0.8% of the company's stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC bought a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 54,464 shares of the biopharmaceutical company's stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences as of its most recent SEC filing. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a "neutral" rating on shares of Assembly Biosciences in a research report on Monday, April 1st. StockNews.com raised shares of Assembly Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, April 5th.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock traded down $0.71 on Friday, reaching $12.65. 29,550 shares of the company traded hands, compared to its average volume of 17,185. Assembly Biosciences has a 52 week low of $7.69 and a 52 week high of $20.04. The company has a 50 day moving average of $13.07 and a 200 day moving average of $11.07. The firm has a market capitalization of $69.32 million, a PE ratio of -0.74 and a beta of 0.57.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.